{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,5]],"date-time":"2026-11-05T02:50:39Z","timestamp":1793847039608,"version":"4.6.1"},"reference-count":21,"publisher":"American Medical Association (AMA)","issue":"12","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JAMA"],"published-print":{"date-parts":[[2021,9,28]]},"abstract":"\n Importance<\/jats:title>\n Preeclampsia is one of the most serious health problems that affect pregnant persons. It is a complication in approximately 4% of pregnancies in the US and contributes to both maternal and infant morbidity and mortality. Preeclampsia also accounts for 6% of preterm births and 19% of medically indicated preterm births in the US. There are racial and ethnic disparities in the prevalence of and mortality from preeclampsia. Non-Hispanic Black women are at greater risk for developing preeclampsia than other women and experience higher rates of maternal and infant morbidity and perinatal mortality.<\/jats:p>\n <\/jats:sec>\n \n Objective<\/jats:title>\n To update its 2014 recommendation, the USPSTF commissioned a systematic review to evaluate the effectiveness of low-dose aspirin use to prevent preeclampsia.<\/jats:p>\n <\/jats:sec>\n \n Population<\/jats:title>\n Pregnant persons at high risk for preeclampsia who have no prior adverse effects with or contraindications to low-dose aspirin.<\/jats:p>\n <\/jats:sec>\n \n Evidence Assessment<\/jats:title>\n The USPSTF concludes with moderate certainty that there is a substantial net benefit of daily low-dose aspirin use to reduce the risk for preeclampsia, preterm birth, small for gestational age\/intrauterine growth restriction, and perinatal mortality in pregnant persons at high risk for preeclampsia.<\/jats:p>\n <\/jats:sec>\n \n Recommendation<\/jats:title>\n The USPSTF recommends the use of low-dose aspirin (81 mg\/d) as preventive medication for preeclampsia after 12 weeks of gestation in persons who are at high risk for preeclampsia. (B recommendation)<\/jats:p>\n <\/jats:sec>","DOI":"10.1001\/jama.2021.14781","type":"journal-article","created":{"date-parts":[[2021,9,28]],"date-time":"2021-09-28T14:48:51Z","timestamp":1632840531000},"page":"1186","source":"Crossref","is-referenced-by-count":407,"title":["Aspirin Use to Prevent Preeclampsia and Related Morbidity and Mortality"],"prefix":"10.1001","volume":"326","author":[{"name":"US Preventive Services Task Force","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Karina W.","family":"Davidson","sequence":"additional","affiliation":[{"name":"Feinstein Institutes for Medical Research at Northwell Health, Manhasset, New York"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael J.","family":"Barry","sequence":"additional","affiliation":[{"name":"Harvard Medical School, Boston, Massachusetts"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carol M.","family":"Mangione","sequence":"additional","affiliation":[{"name":"University of California, Los Angeles"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael","family":"Cabana","sequence":"additional","affiliation":[{"name":"Albert Einstein College of Medicine, New York, New York"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aaron B.","family":"Caughey","sequence":"additional","affiliation":[{"name":"Oregon Health & Science University, Portland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Esa M.","family":"Davis","sequence":"additional","affiliation":[{"name":"University of Pittsburgh, Pittsburgh, Pennsylvania"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Katrina E.","family":"Donahue","sequence":"additional","affiliation":[{"name":"University of North Carolina at Chapel Hill"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chyke A.","family":"Doubeni","sequence":"additional","affiliation":[{"name":"Mayo Clinic, Rochester, Minnesota"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Martha","family":"Kubik","sequence":"additional","affiliation":[{"name":"George Mason University, Fairfax, Virginia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Li","family":"Li","sequence":"additional","affiliation":[{"name":"University of Virginia, Charlottesville"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gbenga","family":"Ogedegbe","sequence":"additional","affiliation":[{"name":"New York University, New York, New York"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lori","family":"Pbert","sequence":"additional","affiliation":[{"name":"University of Massachusetts Medical School, Worcester"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael","family":"Silverstein","sequence":"additional","affiliation":[{"name":"Boston University, Boston, Massachusetts"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Melissa A.","family":"Simon","sequence":"additional","affiliation":[{"name":"Northwestern University, Chicago, Illinois"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"James","family":"Stevermer","sequence":"additional","affiliation":[{"name":"University of Missouri, Columbia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chien-Wen","family":"Tseng","sequence":"additional","affiliation":[{"name":"University of Hawaii, Honolulu"},{"name":"Pacific Health Research and Education Institute, Honolulu, Hawaii"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John B.","family":"Wong","sequence":"additional","affiliation":[{"name":"Tufts University School of Medicine, Boston, Massachusetts"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"10","reference":[{"issue":"3","key":"jus210022r3","first-page":"283","article-title":"Racial\/ethnic differences in pregnancy-related hypertensive disease in nulliparous women.","volume":"24","author":"Ghosh","year":"2014","journal-title":"Ethn Dis"},{"key":"jus210022r4","doi-asserted-by":"publisher","DOI":"10.1016\/j.ajog.2020.07.038","article-title":"Does race or ethnicity play a role in the origin, pathophysiology, and outcomes of preeclampsia? an expert review of the literature.","author":"Johnson","year":"2020","journal-title":"Am J Obstet Gynecol"},{"issue":"1","key":"jus210022r6","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1097\/AOG.0000000000003018","article-title":"ACOG Practice Bulletin No. 202: gestational hypertension and preeclampsia.","volume":"133","author":"American College of Obstetricians and Gynecologists","year":"2019","journal-title":"Obstet Gynecol"},{"issue":"16","key":"jus210022r7","doi-asserted-by":"publisher","first-page":"1668","DOI":"10.1001\/jama.2016.18315","article-title":"Preeclampsia screening: evidence report and systematic review for the US Preventive Services Task Force.","volume":"317","author":"Henderson","year":"2017","journal-title":"JAMA"},{"issue":"7","key":"jus210022r8","doi-asserted-by":"publisher","first-page":"613","DOI":"10.1056\/NEJMoa1704559","article-title":"Aspirin versus placebo in pregnancies at high risk for preterm preeclampsia.","volume":"377","author":"Rolnik","year":"2017","journal-title":"N Engl J Med"},{"issue":"2","key":"jus210022r9","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD004659.pub2","article-title":"Antiplatelet agents for preventing pre-eclampsia and its complications.","volume":"2","author":"Duley","year":"2007","journal-title":"Cochrane Database Syst Rev"},{"issue":"9575","key":"jus210022r10","doi-asserted-by":"publisher","first-page":"1791","DOI":"10.1016\/S0140-6736(07)60712-0","article-title":"Antiplatelet agents for prevention of pre-eclampsia: a meta-analysis of individual patient data.","volume":"369","author":"Askie","year":"2007","journal-title":"Lancet"},{"issue":"16","key":"jus210022r12","doi-asserted-by":"publisher","first-page":"1661","DOI":"10.1001\/jama.2017.3439","article-title":"Screening for preeclampsia: US Preventive Services Task Force recommendation statement.","volume":"317","author":"Bibbins-Domingo","year":"2017","journal-title":"JAMA"},{"issue":"2","key":"jus210022r13","doi-asserted-by":"publisher","first-page":"183","DOI":"10.1001\/jama.2016.19438","article-title":"Folic acid supplementation for the prevention of neural tube defects: US Preventive Services Task Force recommendation statement.","volume":"317","author":"Bibbins-Domingo","year":"2017","journal-title":"JAMA"},{"issue":"11","key":"jus210022r14","doi-asserted-by":"publisher","first-page":"819","DOI":"10.7326\/M14-1884","article-title":"Low-dose aspirin use for the prevention of morbidity and mortality from preeclampsia: U.S. Preventive Services Task Force recommendation statement.","volume":"161","author":"LeFevre","year":"2014","journal-title":"Ann Intern Med"},{"key":"jus210022r15","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2021.8551","article-title":"Aspirin use to prevent preeclampsia and related morbidity and mortality: updated evidence report and systematic review for the US Preventive Services Task Force.","author":"Henderson","journal-title":"JAMA"},{"issue":"11","key":"jus210022r16","doi-asserted-by":"publisher","first-page":"701","DOI":"10.1056\/NEJM199803123381101","article-title":"Low-dose aspirin to prevent preeclampsia in women at high risk.","volume":"338","author":"Caritis","year":"1998","journal-title":"N Engl J Med"},{"issue":"8898","key":"jus210022r17","doi-asserted-by":"publisher","first-page":"619","DOI":"10.1016\/S0140-6736(94)92633-6","article-title":"CLASP: a randomised trial of low-dose aspirin for the prevention and treatment of pre-eclampsia among 9364 pregnant women.","volume":"343","author":"CLASP (Collaborative Low-dose Aspirin Study in Pregnancy) Collaborative Group","year":"1994","journal-title":"Lancet"},{"issue":"11","key":"jus210022r18","doi-asserted-by":"publisher","first-page":"861","DOI":"10.1111\/j.1471-0528.1995.tb10872.x","article-title":"Low dose aspirin in pregnancy and early childhood development: follow up of the collaborative low dose aspirin study in pregnancy.","volume":"102","author":"CLASP Collaborative Group","year":"1995","journal-title":"Br J Obstet Gynaecol"},{"issue":"1","key":"jus210022r19","doi-asserted-by":"publisher","first-page":"e44","DOI":"10.1097\/AOG.0000000000002708","article-title":"ACOG Committee Opinion No. 743: low-dose aspirin use during pregnancy.","volume":"132","author":"American College of Obstetricians and Gynecologists","year":"2018","journal-title":"Obstet Gynecol"},{"issue":"5","key":"jus210022r21","doi-asserted-by":"publisher","first-page":"1545","DOI":"10.1161\/01.str.0000442009.06663.48","article-title":"Guidelines for the prevention of stroke in women: a statement for healthcare professionals from the American Heart Association\/American Stroke Association.","volume":"45","author":"Bushnell","year":"2014","journal-title":"Stroke"},{"key":"jus210022r1","doi-asserted-by":"crossref","DOI":"10.1001\/jama.2021.8551","volume-title":"Aspirin Use to Prevent Preeclampsia and Related Morbidity and Mortality: An Evidence Update for the U.S. Preventive Services Task Force. Evidence Synthesis No. 205","author":"Henderson","year":"2021"},{"key":"jus210022r2","volume-title":"Delivery Hospitalizations Involving Preeclampsia and Eclampsia, 2005\u20132014: Statistical Brief No. 222.","author":"Fingar","year":"2017"},{"key":"jus210022r5","unstructured":"Procedure Manual. US Preventive Services Task Force. Published May 2021. Accessed August 2, 2021. https:\/\/uspreventiveservicestaskforce.org\/uspstf\/about-uspstf\/methods-and-processes\/procedure-manual"},{"key":"jus210022r11","unstructured":"US Food and Drug Administration. FDA Drug Safety Communication: FDA recommends avoiding use of NSAIDs in pregnancy at 20 weeks or later because they can result in low amniotic fluid. Published October 15, 2020. Accessed August 2, 2021. https:\/\/www.fda.gov\/media\/142967\/download"},{"key":"jus210022r20","unstructured":"WHO Recommendations for Prevention and Treatment of Pre-Eclampsia and Eclampsia. World Health Organization. Published 2011. Accessed August 2, 2021. https:\/\/www.who.int\/reproductivehealth\/publications\/maternal_perinatal_health\/9789241548335\/en\/"}],"container-title":["JAMA"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/jamanetwork.com\/journals\/jama\/articlepdf\/2784499\/jama_davidson_2021_us_210022_1776348933.68921.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,16]],"date-time":"2026-04-16T15:00:51Z","timestamp":1776351651000},"score":1,"resource":{"primary":{"URL":"https:\/\/jamanetwork.com\/journals\/jama\/fullarticle\/2784499"}},"subtitle":["US Preventive Services Task Force Recommendation Statement"],"short-title":[],"issued":{"date-parts":[[2021,9,28]]},"references-count":21,"journal-issue":{"issue":"12","published-print":{"date-parts":[[2021,9,28]]}},"URL":"https:\/\/doi.org\/10.1001\/jama.2021.14781","relation":{},"ISSN":["0098-7484"],"issn-type":[{"value":"0098-7484","type":"print"}],"subject":[],"published":{"date-parts":[[2021,9,28]]}}}